Related references
Note: Only part of the references are listed.Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study
Ralf Gold et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study
Ralf Gold et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Disease-modifying treatments for multiple sclerosis - a review of approved medications
O. Torkildsen et al.
EUROPEAN JOURNAL OF NEUROLOGY (2016)
Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients
Erin E. Longbrake et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients
Erin E. Longbrake et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Interferon-β therapy specifically reduces pathogenic memory B cells in multiple sclerosis patients by inducing a FAS-mediated apoptosis
Fabiana Rizzo et al.
IMMUNOLOGY AND CELL BIOLOGY (2016)
Disease modifying therapies for relapsing multiple sclerosis
Dean M. Wingerchuk et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Disease modifying therapies for relapsing multiple sclerosis
Dean M. Wingerchuk et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Dimethyl fumarate blocks proinflammatory cytokine production via inhibition of TLR induced M1 and K63 ubiquitin chain formation
Victoria A. McGuire et al.
SCIENTIFIC REPORTS (2016)
Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets
Steven K. Lundy et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2016)
Effects of fumarates on circulating and CNS myeloid cells in multiple sclerosis
Mackenzie A. Michell-Robinson et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2016)
Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis
Catharina C. Gross et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2016)
Alemtuzumab long-term immunologic effect Treg suppressor function increases up to 24 months
Stefania De Mercanti et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2016)
Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies
Ralf Gold et al.
NEUROLOGY AND THERAPY (2016)
Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety
Duvyanshu Dubey et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2015)
Dimethyl Fumarate Protects Neural Stem/Progenitor Cells and Neurons from Oxidative Damage through Nrf2-ERK1/2 MAPK Pathway
Qin Wang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
Multiple sclerosis-a quiet revolution
Richard M. Ransohoff et al.
NATURE REVIEWS NEUROLOGY (2015)
Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety
Duvyanshu Dubey et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2015)
Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort
Dalia L. Rotstein et al.
JAMA NEUROLOGY (2015)
Is it time to target no evident disease activity (NEDA) in multiple sclerosis?
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2015)
Peripheral Blood T Cell Dynamics Predict Relapse in Multiple Sclerosis Patients on Fingolimod
Zi-Ye Song et al.
PLOS ONE (2015)
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Robert J. Fox et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Ralf Gold et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis
J. E. Martinez-Rodriguez et al.
CLINICAL IMMUNOLOGY (2011)
Abnormal B-Cell Cytokine Responses A Trigger of T-Cell Mediated Disease in MS?
Amit Bar-Or et al.
ANNALS OF NEUROLOGY (2010)
CD56bright natural killer (NK) cells: an important NK cell subset
Aurelie Poli et al.
IMMUNOLOGY (2009)
Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta
M. Saraste et al.
NEUROLOGICAL SCIENCES (2007)
Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis
Martin Duddy et al.
JOURNAL OF IMMUNOLOGY (2007)
Increased CD8+ central memory T cells in patients with multiple sclerosis
Guang-Zhi Liu et al.
MULTIPLE SCLEROSIS JOURNAL (2007)
Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis
B Bielekova et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Dimethylfumarate inhibits TNF-induced nuclear entry of NF-κB/p65 in human endothelial cells
R Loewe et al.
JOURNAL OF IMMUNOLOGY (2002)
Human natural killer cells:: a unique innate immunoregulatory role for the CD56bright subset
MA Cooper et al.
BLOOD (2001)
Share Paper
